2019
Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States
Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.Peer-Reviewed Original ResearchConceptsBone-modifying drugsSupportive careMultiple myelomaInfluenza vaccinationAntiviral prophylaxisOlder adultsLower oddsEnd Results-Medicare databaseNon-Hispanic black patientsMultivariable logistic regression modelBaseline renal impairmentSupportive care useTreatment-related toxicityFacility-level characteristicsNon-Hispanic blacksOutcomes of interestCommunity-based settingsLogistic regression modelsRenal impairmentActive treatmentBlack patientsCare useConcomitant useProphylactic antiviralsReduced odds
2018
Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States
Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States. Blood 2018, 132: 978. DOI: 10.1182/blood-2018-99-119791.Peer-Reviewed Original ResearchSupportive care measuresMultiple myelomaInfluenza vaccinationMM therapySupportive careCare measuresFlu seasonAntiviral prophylaxisComorbidity burdenMedicare beneficiariesPre-existing chronic kidney diseaseContinuous Medicare Parts ANon-Hispanic black ethnicityMultivariable logistic regression modelRacial disparitiesHigher comorbidity burdenLower comorbidity burdenNovel MM therapiesSupportive care therapySupportive care useEnd Results-MedicareTreatment-related toxicityChronic kidney diseaseProportion of patientsYear of diagnosis
2017
R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis
Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan‐Dabaja M, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis. British Journal Of Haematology 2017, 180: 534-544. PMID: 29265182, DOI: 10.1111/bjh.15051.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDisease ManagementDoxorubicinEtoposideFemaleHumansLymphoma, B-CellMaleMediastinal NeoplasmsMiddle AgedNeoplasm GradingNeoplasm StagingPrednisoneRecurrenceRetrospective StudiesRituximabTreatment FailureTreatment OutcomeVincristineYoung AdultConceptsPrimary mediastinal large B-cell lymphomaDA-R-EPOCHDose-adjusted R-EPOCHNon-Hodgkin lymphomaB-cell lymphomaR-CHOPR-EPOCHMediastinal large B-cell lymphomaPrimary mediastinal B-cell lymphomaLarge B-cell lymphomaR-CHOP patientsComplete response rateMediastinal B-cell lymphomaTreatment-related complicationsPhase II trialProgression-free survivalR-CHOP chemotherapyTreatment-related toxicityUnique clinicopathological featuresMulti-center analysisII trialOverall survivalSecondary outcomesPrimary outcomeClinicopathological features
2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy
Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 2012, 53: 1461-1468. PMID: 22260160, PMCID: PMC7845767, DOI: 10.3109/10428194.2012.658793.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsComorbidityCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleGeriatricsHumansLymphoma, Large B-Cell, DiffuseMaleMedical OncologyMiddle AgedPrednisoneRemission InductionRetrospective StudiesRituximabTreatment OutcomeVincristineConceptsNon-Hodgkin lymphomaLarge cell lymphomaCell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaChemotherapy dose reductionsTreatment-related toxicityR-CHOP treatmentSingle-institution studyB-cell lymphomaCurative intentRelative chemotherapyComplete remissionPrimary therapyElderly patientsSupportive careTreatment toxicityAged patientsPatient populationTreatment outcomesRetrospective analysisDose reductionElderly populationPatientsLymphoma